       |
Therapeutic apheresis is provided primarily for category I conditions. Therapeutic apheresis is considered standard and acceptable under most circumstances for the following conditions:
A. Neurological disorders with established indications for plasma exchange:
1. Myasthenia Gravis and Eton-Lambert syndrome.
2. Guillian-barre syndrome (acute inflammatory
demyelinating polyneuropathy).
B. Other peripheral neuropathies:
1. Chronic inflammatory demyelinating polyneuropathy.
2. HIV-related peripheral neuropathy.
3. Paraprotein-related neuropathy.
C. Other autoimmune conditions including Goodpasture's syndrome, and coagulation factor (factor 8) inhibitors. Systemic lupus, under specific circumstances may meet criteria for apheresis intervention.
D. Cryoglobulinemia.
E. Hyperviscosity syndrome (Waldrenstrom's Disease
and multiple myeloma with hyperviscosity).
F. Thrombotic thrombocytopenic purpura (TTP)
and hemolytic uremic syndrome (HUS).
G. Hematological disorders necessitating cytoreductive apheresis for:
1. Symptomatic leukostasis
2. Pre-induction cytoreduction
3. Symptomatic thrombocytosis
